Overview

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2017-04-24

Target enrollment:

Participant gender:

Summary

This is an international, multi-center, prospective, randomized, open-label Phase 3 clinical trial of the cancer stemness inhibitor napabucasin administered with weekly paclitaxel versus weekly paclitaxel alone in patients with advanced non-squamous non-small cell lung cancer who have disease progression following systemic treatment with a platinum-based combination regimen in the metastatic setting, who have received treatment with an immune checkpoint inhibitor if a candidate, additional approved therapies, and for whom weekly paclitaxel is an acceptable treatment option.

Phase:

Phase 3

Details

Lead Sponsor:

Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel